The data described in Table 1 and Fig. 1 suggest that the pre-existence of subclones carrying RAS but not EGFR ECD mutations affects the clinical outcome of CRC patients treated with cetuximab or panitumumab. The gene discussed is EGFR; the disease is colorectal carcinoma.